BSE · 532167
Omkar Pharmachem Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹0 Cr with net profit ₹0 Cr — a 25.78% net margin, versus 37.05% the period before.
Shareholding
As of 2026-09-30
- Promoter0.03%
- Public99.97%
3,861 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 4.76× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — GSM · GSM 2. Trading may carry price bands, periodic call auction or higher margins.
Peer comparison
Miscellaneous · ranked #403 of 552 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| National Stock Exchange Of India Ltd. | ₹4,42,765 Cr | 49.53 | 13.79 | 22.8% | 64.54% |
| Adani Ports & Special Economic Zone Ltd. | ₹4,31,301 Cr | 31.19 | 4.17 | 13.33% | 31.98% |
| Eternal Limited | ₹3,26,037 Cr | 662.45 | 10.41 | 1.58% | 0.63% |
| BSE Limited | ₹1,42,841 Cr | 50.45 | 21.41 | 37.42% | 52.03% |
| Vedanta Aluminium Metal Limited | ₹1,36,453 Cr | 11.36 | 5.92 | 80.07% | 23.43% |
| GAIL (India) Ltd. | ₹1,08,601 Cr | 11 | 1.22 | 8.51% | 6.67% |
| One 97 Communications Ltd. | ₹1,08,337 Cr | 129.23 | 6.53 | 5.15% | 8.95% |
| Meesho Limited | ₹1,04,040 Cr | — | 24.72 | -21.93% | -6.19% |
| GMR Airports Limited | ₹93,038 Cr | 155.84 | 0 | -25.64% | 3.13% |
| Multi Commodity Exchange of India Ltd. | ₹82,388 Cr | 53.44 | 28.91 | 46.75% | 58.61% |
| Omkar Pharmachem Ltd.(this company) | ₹6 Cr | 78.13 | 0.17 | 0.33% | 0% |
AI analysis
AI-generated · google/gemini-2.5-flashOmkar Pharmachem Ltd. is listed on the Indian markets with a market capitalization of Rs 16 Cr. The company reported a revenue of Rs 0.54 Cr. The trailing twelve months EPS stands at Rs 0.12, with a P/E ratio of 136.25. Its book value per share is Rs 36.34. The latest available shareholding data from March 2026 indicates promoter holding of 0.0258% and public holding of 99.9742%.
Positives
- +The debt-to-equity ratio is low at 0.02.
- +The Return on Equity (ROE) is 33.2% based on the latest available data.
Negatives
- −The promoter shareholding is very low at 0.0258% as of March 2026.
- −The profit margin is 0% based on the latest annual data.
- −Revenue has seen a decline in recent quarters, from Rs 0.14 Cr in Dec 2024 to Rs 0.09 Cr in Mar 2026.
- −The Return on Capital Employed (ROCE) is low at 0.45%.
- −No dividend has been declared, resulting in a dividend yield of 0%.
Financial performance
Omkar Pharmachem Ltd. recorded a revenue of Rs 0.54 Cr for the fiscal year ending March 2022, which remained largely consistent in subsequent years, reaching Rs 0.5435 Cr in March 2024 and Rs 0.5422 Cr in March 2025. Annual net profit was Rs 0.2214 Cr in March 2021, and Rs 0.2009 Cr in March 2025. Quarterly revenue has shown a decline, from Rs 0.14 Cr in December 2024 to Rs 0.09 Cr in March 2026.
Profitability & Returns
The company's Return on Equity (ROE) is 33.2%. The Return on Capital Employed (ROCE) is 0.45%. The earnings per share (EPS) for the trailing twelve months is Rs 0.12. The profit margin for the latest annual reporting period is 0%. The company has not declared any dividends, with a dividend yield of 0%.
Balance Sheet
Omkar Pharmachem Ltd. maintains a low debt-to-equity ratio of 0.02, indicating minimal reliance on borrowed funds. The book value per share is Rs 36.34. This suggests a relatively strong balance sheet in terms of debt management.
Ownership & Pledges
As of March 2026, the promoter holding in Omkar Pharmachem Ltd. There is no reported pledged promoter shareholding (0%). The number of shareholders is 3617. No institutional holding (DII or FII) has been reported.
Data as of — price: 2026-10-30 · financials: Mar 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.